Empros Pharma doses first patients in large scale clinical study of anti-obesity drug EMP-16
Empros Pharma AB announces today that they have dosed the first patients with anti-obesity drug,
EMP-16 in the third clinical study. The phase 2 trial known as the SESAM study has begun with
dosing patients at each clinic in Uppsala, …